TDC
ATRC icon

Thompson Davis & Co’s AtriCure ATRC Stock Holding History

Thompson Davis & Co’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,031
Closed -$20K – 1076
2017
Q1 		$20K Hold
1,031
– – 0.03% 486
2016
Q4 		$20K Buy
+1,031
New +$18.7K 0.03% 495

Other funds holding ATRC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Thompson Davis & Co's ATRC Position: Q2 2017 in Review

Thompson Davis & Co sold out of AtriCure (ATRC) in Q2 2017, closing a stake of 1,031 shares — an estimated $20K sold.

Thompson Davis & Co first reported a position in ATRC in Q4 2016 and held it in 2 quarters. The position peaked at $20K in Q1 2017. 107 funds tracked by Wall St. Rank hold ATRC as of Q2 2017.

  • Thompson Davis & Co reported no remaining AtriCure position as of Q2 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 1,031 AtriCure shares in Q2 2017, an estimated $20K.
  • Thompson Davis & Co first reported a position in AtriCure in Q4 2016 and held it in 2 quarters.
  • Thompson Davis & Co's AtriCure position peaked at $20K in Q1 2017.
  • 107 funds tracked by Wall St. Rank held AtriCure as of Q2 2017.

Based on Thompson Davis & Co's 13F filing for Q2 2017, filed 10 Aug 2017.